208 related articles for article (PubMed ID: 25092427)
1. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Gallo A; Bouchard C; Fortier E; Ducrot C; Rompré PP
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1534-45. PubMed ID: 25092427
[TBL] [Abstract][Full Text] [Related]
2. Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference.
Gallo A; Bouchard C; Rompré PP
Behav Brain Res; 2014 Jul; 268():202-12. PubMed ID: 24755307
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.
Lefever TW; Marusich JA; Antonazzo KR; Wiley JL
Pharmacol Biochem Behav; 2014 Mar; 118():30-5. PubMed ID: 24412835
[TBL] [Abstract][Full Text] [Related]
4. Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.
Scherma M; Dessì C; Muntoni AL; Lecca S; Satta V; Luchicchi A; Pistis M; Panlilio LV; Fattore L; Goldberg SR; Fratta W; Fadda P
Neuropsychopharmacology; 2016 Apr; 41(5):1416-26. PubMed ID: 26388146
[TBL] [Abstract][Full Text] [Related]
5. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.
Vlachou S; Nomikos GG; Panagis G
Psychopharmacology (Berl); 2005 May; 179(2):498-508. PubMed ID: 15821959
[TBL] [Abstract][Full Text] [Related]
6. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
7. Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia.
Brady AM; McCallum SE; Glick SD; O'Donnell P
Psychopharmacology (Berl); 2008 Oct; 200(2):205-15. PubMed ID: 18500636
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.
Vlachou S; Stamatopoulou F; Nomikos GG; Panagis G
Int J Neuropsychopharmacol; 2008 Nov; 11(7):905-23. PubMed ID: 18377702
[TBL] [Abstract][Full Text] [Related]
9. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward.
Flores Á; Maldonado R; Berrendero F
Biol Psychiatry; 2014 Mar; 75(6):499-507. PubMed ID: 23896204
[TBL] [Abstract][Full Text] [Related]
10. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation.
Vlachou S; Nomikos GG; Panagis G
Behav Brain Res; 2003 May; 141(2):215-22. PubMed ID: 12742258
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention deficit hyperactivity disorder.
Pandolfo P; Vendruscolo LF; Sordi R; Takahashi RN
Psychopharmacology (Berl); 2009 Aug; 205(2):319-26. PubMed ID: 19407992
[TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
13. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
14. Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.
Spano MS; Fattore L; Cadeddu F; Fratta W; Fadda P
Psychopharmacology (Berl); 2013 Feb; 225(3):531-42. PubMed ID: 22903392
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function.
Fattore L; Spano MS; Altea S; Angius F; Fadda P; Fratta W
Br J Pharmacol; 2007 Nov; 152(5):795-804. PubMed ID: 17891164
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.
Polissidis A; Chouliara O; Galanopoulos A; Naxakis G; Papahatjis D; Papadopoulou-Daifoti Z; Antoniou K
Behav Brain Res; 2014 Aug; 270():261-9. PubMed ID: 24867330
[TBL] [Abstract][Full Text] [Related]
17. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
Fattore L; Cossu G; Martellotta CM; Fratta W
Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
[TBL] [Abstract][Full Text] [Related]
18. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.
Gomes FV; Guimarães FS; Grace AA
Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522381
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats.
Spano MS; Fadda P; Frau R; Fattore L; Fratta W
Eur Neuropsychopharmacol; 2010 Jan; 20(1):25-36. PubMed ID: 19854030
[TBL] [Abstract][Full Text] [Related]
20. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
